Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
about
Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-AnalysisTapentadol extended release for the management of chronic neck pain.Health-related quality of life in patients receiving long-term opioid therapy: a systematic review with meta-analysis.Is tapentadol different from classical opioids? A review of the evidence.Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release.Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain.Oral prolonged-release oxycodone/naloxone for managing pain and opioid-induced constipation: A review of the evidence.Methodological Aspects in Studies Based on Clinical Routine Data.Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.Considering tapentadol as a first-line analgesic: 14 questions.Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia.Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson's disease
P2860
Q31128284-8D75F92C-6C9A-4AF2-AFC3-5BBDC6857287Q33700472-31CAC596-0B6A-4956-BA4D-8BD3D861329CQ37682809-C7DFB1A2-B7EA-4FCD-B89E-B27825A7A496Q38931869-882FE6A4-DD61-4EA6-B785-78B828771702Q39014916-50412CA7-9CF1-4EAF-8253-744B14896D5EQ42936194-B7F2A2DC-2CE7-4691-963A-593878DCF272Q43075620-AE92E6FC-7D71-4815-B966-388B23351A87Q43075972-FACFA26E-89D7-4CC8-8F79-A23D1F3777CAQ43211616-53B5E265-55A4-4619-A0CB-FDA24CE070E9Q47261672-9E927574-58B4-4028-995C-36DB0918ED59Q52603231-77BF7456-CEC7-468C-B5B8-A4A18F69E420Q53339459-BD513739-9C22-40CA-AFB0-46C15D2D91C5Q55023336-C6DFF68E-954C-45E3-A8FB-571C0C400087Q57111444-86021069-0387-4D1B-BFAA-6E4001ABBDEA
P2860
Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Tolerability, Safety, and Qual ...... Open-label, Phase 3b/4 Trial.
@en
Tolerability, Safety, and Qual ...... Open-label, Phase 3b/4 Trial.
@nl
type
label
Tolerability, Safety, and Qual ...... Open-label, Phase 3b/4 Trial.
@en
Tolerability, Safety, and Qual ...... Open-label, Phase 3b/4 Trial.
@nl
prefLabel
Tolerability, Safety, and Qual ...... Open-label, Phase 3b/4 Trial.
@en
Tolerability, Safety, and Qual ...... Open-label, Phase 3b/4 Trial.
@nl
P2093
P2860
P921
P356
P1433
P1476
Tolerability, Safety, and Qual ...... Open-label, Phase 3b/4 Trial.
@en
P2093
Andreas Binder
Dietmar Falke
Ilona Steigerwald
Jan-Peter Jansen
Lieven Kennes
Manuel Pombo-Suarez
Matthias Müller
Ralf Baron
P2860
P304
P356
10.1111/PAPR.12361
P577
2015-11-11T00:00:00Z